Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Aquestive Therapeutics, Inc. has received an average rating of "Moderate Buy" from eleven analysts, with eight assigning a buy recommendation and one issuing a strong buy.
• The company's stock price target among brokers is set at an average of $10.71, while it currently trades around $7.01.
• Insider selling was notable, with COO Cassie Jung and another insider collectively selling over 77,000 shares recently, indicating a potential decrease in insider confidence.

Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $10.7143.

AQST has been the topic of several recent research reports. Zacks Research upgraded Aquestive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 13th. Lifesci Capital upgraded Aquestive Therapeutics to a "strong-buy" rating in a report on Wednesday, September 3rd. JMP Securities increased their price target on Aquestive Therapeutics from $9.00 to $12.00 and gave the company a "market outperform" rating in a report on Thursday, October 9th. Weiss Ratings restated a "sell (d-)" rating on shares of Aquestive Therapeutics in a report on Wednesday, October 8th. Finally, Citigroup reaffirmed an "outperform" rating on shares of Aquestive Therapeutics in a research report on Thursday, October 9th.

Insider Buying and Selling at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Peter E. Boyd sold 15,000 shares of the company's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $5.30, for a total value of $79,500.00. Following the transaction, the insider owned 288,323 shares of the company's stock, valued at $1,528,111.90. This represents a 4.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Cassie Jung sold 62,180 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $5.00, for a total value of $310,900.00. Following the completion of the transaction, the chief operating officer directly owned 283,346 shares in the company, valued at $1,416,730. This trade represents a 18.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 178,923 shares of company stock valued at $1,006,598 in the last quarter. 8.35% of the stock is owned by insiders.

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds have recently bought and sold shares of AQST. Summit Wealth & Retirement Planning Inc. bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth $29,000. Victory Capital Management Inc. bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth $31,000. BNP Paribas Financial Markets grew its position in shares of Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company's stock worth $31,000 after buying an additional 4,134 shares in the last quarter. Cambridge Investment Research Advisors Inc. bought a new position in shares of Aquestive Therapeutics during the 1st quarter worth $33,000. Finally, USAdvisors Wealth Management LLC bought a new position in shares of Aquestive Therapeutics during the 2nd quarter worth $33,000. Institutional investors own 32.45% of the company's stock.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST opened at $7.01 on Friday. The stock's fifty day moving average is $5.00 and its 200 day moving average is $3.81. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $7.51. The firm has a market capitalization of $699.04 million, a PE ratio of -10.01 and a beta of 1.77.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $10.00 million for the quarter, compared to analysts' expectations of $11.32 million. Aquestive Therapeutics has set its FY 2025 guidance at EPS. Equities analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current year.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.